These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 3079086)
41. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279 [No Abstract] [Full Text] [Related]
48. Important role for mannitol in the prevention of acute renal failure after cadaveric kidney transplantation. Hoitsma AJ; Groenewoud AF; Berden JH; van Lier HJ; Koene RA Transplant Proc; 1987 Feb; 19(1 Pt 3):2063-4. PubMed ID: 3152658 [No Abstract] [Full Text] [Related]
49. Induction of ICAM-1 on hepatocyte membranes during liver allograft rejection and infection. Steinhoff G; Behrend M; Pichlmayr R Transplant Proc; 1990 Oct; 22(5):2308-9. PubMed ID: 2219382 [No Abstract] [Full Text] [Related]
50. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation. Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207 [No Abstract] [Full Text] [Related]
51. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103 [TBL] [Abstract][Full Text] [Related]
52. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. Monden M; Gotoh M; Kanai T; Valdivia LA; Umeshita K; Endoh W; Nakano Y; Kawai M; Ohzato H; Ukei T Transplant Proc; 1990 Feb; 22(1):66-71. PubMed ID: 1689904 [No Abstract] [Full Text] [Related]
54. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826 [No Abstract] [Full Text] [Related]
55. OKT3 prophylaxis in liver transplant patients: a European and Australian multicenter, prospective controlled trial. Höckerstedt K; Ericzon BG; Bismuth H; Chapuis Y; Farges O; Faure JL; Galmarini D; Houssin D; Lynch SV; Miguet J Transplant Proc; 1993 Feb; 25(1 Pt 1):556-7. PubMed ID: 8438412 [No Abstract] [Full Text] [Related]
56. Improved early course after cadaveric renal transplantation by reducing the cyclosporine dose and adding azathioprine. Lundgren G; Albrechtsen D; Brynger H; Flatmark A; Frödin I; Gäbel H; Persson H; Groth CG Transplant Proc; 1987 Feb; 19(1 Pt 3):2074-9. PubMed ID: 3547910 [No Abstract] [Full Text] [Related]
57. Cyclosporine in transplantation of the liver in the dog. Williams JW; Peters TG; Haggitt R; Van Voorst S Surg Gynecol Obstet; 1983 Jun; 156(6):767-73. PubMed ID: 6344281 [TBL] [Abstract][Full Text] [Related]
58. Experience in therapy of chronic liver allograft rejection. Charco R; Ruiz C; Allende E; Balsells J; Lazaro JL; Murio E; Bilbao I; Gifre E; Margarit C Transplant Proc; 1995 Aug; 27(4):2293-4. PubMed ID: 7652811 [No Abstract] [Full Text] [Related]
59. Immune monitoring during retreatment with OKT3. First MR; Schroeder TJ; Hurtubise PE; Mansour ME; Penn I; Munda R; Balistreri WF; Alexander JW; Melvin DB; Fidler JP Transplant Proc; 1989 Feb; 21(1 Pt 2):1753-4. PubMed ID: 2652573 [No Abstract] [Full Text] [Related]